Publications &
Presentations

Introducing CLE-400; Topical Alpha-2-Adrenergic Agonist as a First-in-Class Treatment for Localized Chronic Pruritus
Mary Spellman, M.D.

Introducing SPRACISE a Novel Platform for Localized Deep Nasal Delivery
Shai Assia

A Phase 2 Randomized Controlled Adjunctive Treatment Trial with CLE-100 Esketamine Tablet for Patients with Major Depressive Disorder and Inadequate Response to Antidepressants, During the COVID-19 Pandemic
Maurizio Fava, Oren Berkowitz, Sanjay J. Mathew, Michael E. Thase, Andrew A. Nierenberg, Dan V. Iosifescu, L. Alison McInnes, Cristina Cusin, Robert Berman, Eli Eyal, Ari Gershon, Esther Lukasiewicz-Hagai

High Unmet Medical Need in Brachioradial Pruritus: Results from a Large Patient Survey
Elinor Artsy Navon, MD

Dysphagia and its Relationship to Medication Intake in Parkinson's Disease
Elijahu Berkovich, PhD and Dorit Mimrod, PhD

OLAR®: A Novel Oral Long Acting Release (OLAR®) platform
Menashe Levy

Sleep problems in Parkinson’s Disease: PD patients’ survey on common issues and treatments expectations
Elijahu Berkovich, PhD

CLE-400 for Chronic Neuropathic Itch
Yael Rosen, MD

CLE-600: Treating nocturnal and early morning OFF symptomology in Parkinson's disease with the OLAR platform Elijahu Berkovich, PhD

CLE 400 a potent alpha 2 adrenergic receptor agonist for the treatment of chronic itch
Elanite Caspi, PhD

CLE-400 a Potent Analgesic Topical Gel in Acute and Chronic Pain Pig Models.
Elanite Caspi, PhD

CLE-400 a potent alpha 2 adrenergic receptor agonist for the treatment of chronic itch
Johanna Schumann, PhD

CLE-600: Treating nocturnal and early morning OFF symptomology in Parkinson’s disease with the OLAR® platform
Elijahu Berkovich, PhD

CLE-400 a novel non-opioid topical treatment for painful diabetic neuropathy
Orna Goren, PhD

Introducing the OLAR platform
Elijahu Berkovich, PhD